bilaterals.org logo
bilaterals.org logo

intellectual property

Longer monopolies and single legal proceedings vs. generics - the gift of CETA to Canadian drug patentees
13-Dec-2016 Lexology
Canadian pharmaceutical patent owners can expect two substantive changes in the next year following implementation of the Canada–European Union trade agreement
Regional trade meet should not pave way for monopoly in drugs: Doctors without Borders
12-Dec-2016 The Times of India
Doctors Without Borders/Medecins Sans Frontieres (MSF) and other health groups have reiterated concerns about harmful intellectual property provisions in the RCEP
EU-Mexico FTA - EU text proposals (November 2016)
12-Dec-2016 European Commission
As published by the European Commission
TPP may be dead – but its impact lingers
7-Dec-2016 IP Watch
Threats to affordable access to medicines continue unabated
On World AIDS Day, threat to access to medicines looms large
6-Dec-2016 The Jakarta Post
As trade negotiators from 16 countries gather in Indonesia to deliberate the terms of trade agreement — the Regional Comprehensive Economic Partnership agreement (RCEP), access to low-cost generic medicines is under grave threat.
Scrapping TPP won’t make a lick of difference
6-Dec-2016 ABC
The problem with free trade deals is they rarely are about trade. In fact, trade usually is a side issue. And the TPP was a classic case in point.
Canada-EU trade deal: Costs for new drugs may rise, but not for years
2-Dec-2016 CBC
CETA drug-patent extension applies only to new products, and higher costs are likely at least 8 years away
Why Trump is right, and wrong, about killing off the TPP
25-Nov-2016 The Conversation
Trump tells a half truth about why the TPP is a bad deal
Asean integration at the end of 2016
24-Nov-2016 Business Mirror
The launch of the Asean Economic Community (AEC) in December 2015 was a milestone for Asean economic integration, which is, however, an ongoing process.
Ottawa didn’t study how much more we’ll pay for drugs under CETA
22-Nov-2016 Huffington Post
Experts have been warning for years that Canada’s trade deal with the European Union would add billions to the cost of pharmaceuticals in Canada, but the government itself apparently did not study the issue.
Trump is right: Nafta is a disaster. But US workers aren’t the big losers
18-Nov-2016 The Guardian
The president-elect has promised to rip up the free trade treaty, yet there is no sign that his approach will be any fairer
UK and India sign wide-ranging IP agreement
10-Nov-2016 WIPR
The countries will exchange best practices in the IP field, such as streamlining the processing of patent, trademark and design registrations.
What do trade agreements do for open access—and what don’t they do?
27-Oct-2016 Electronic Frontier Foundation
The absence of support for open access in trade agreements comes as no surprise when considering that there are no representatives from the education sector, nor any library or archive representatives, in the relevant closed-door trade advisory committees
Call for Govt to help our neighbours negotiate for life-saving medicines
25-Oct-2016 Newstalk ZB
The Public Health Association (PHA) is asking the NZ government to step in and help our neighbouring countries negotiate better deals for life-saving medicines.
India to US: Will not tighten IPR rules beyond TRIPS mandate
21-Oct-2016 Hindu Business Line
India and the US continued to differ on the issue of intellectual property rights (IPR) norms in their bilateral trade and investment policy discussions
Activists fret about RCEP impact
20-Oct-2016 Bangkok Post
Access to affordable medicine and farmers’ control over seeds could be undermined by the Regional Comprehensive Economic Partnership being negotiated between Asean member countries and six other trade partners, says FTA Watch in Thailand
An open letter to the sixteen governments negotiating the Regional Comprehensive Economic Partnership (RCEP)
17-Oct-2016
95 health, community and development organisations in the Asia Pacific region call on trade negotiators from sixteen countries in the Regional Comprehensive Economic Partnership agreement negotiations to ensure access to medicines is protected. We the undersigned organisations call on negotiators to protect health and reject all TRIPS plus intellectual property measures in the RCEP.
Open letter to ambassadors (in India) of RCEP negotiating countries by Delhi Network of Positive People
13-Oct-2016 Don’t trade our lives away
Member countries must consider the impact of RCEP on access to medicines in developing countries
The Aids revolution is why Asean, India and China must resist controls on generic drugs
11-Oct-2016 South China Morning Post
Affordable generics have transformed medical treatment, yet intellectual property provisions in a China-led regional trade deal could block access to life-saving drugs for millions in Africa and Asia
In boon for Big Pharma, TTIP would lock in high drug prices: report
5-Oct-2016 Common Dreams
’Unfortunately, trade agreements have become one more mechanism for drug corporations to expand their monopoly power’